G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease

Experimental Neurology

Volumn 257, Issue , 2014, Pages 1-9

  Oeckl, Patrick ^a,b   Hengerer, Bastian ^a   Ferger, Boris ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

6 Hydroxydopamine; Apomorphine; CAMP; Dopamine; Dyskinesia; GPR6; In vivo microdialysis; Parkinson's disease

Indexed keywords

CYCLIC AMP; DOPAMINE; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 6; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DYSKINESIA; EXTRACELLULAR SPACE; IN VIVO STUDY; INVOLUNTARY MOVEMENT; LOCOMOTION; MALE; MICRODIALYSIS; MOTOR ACTIVITY; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION;

6-HYDROXYDOPAMINE; APOMORPHINE; CAMP; DOPAMINE; DYSKINESIA; GPR6; IN VIVO MICRODIALYSIS; PARKINSON'S DISEASE;

ADRENERGIC AGENTS; ANIMALS; ANTI-DYSKINESIA AGENTS; CORPUS STRIATUM; CYCLIC AMP; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DYSKINESIAS; HALOPERIDOL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; RECEPTORS, G-PROTEIN-COUPLED; TYROSINE 3-MONOOXYGENASE;

EID: 84899687219     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.04.010     Document Type: Article

References (33)

1. Bateup H.S., Svenningsson P., Kuroiwa M., Gong S., Nishi A., Heintz N., Greengard P. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 2008, 11:932-939.
2. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N., Chen J.F., Schwarzschild M.A., Chase T.N. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 2003, 184:285-294.
3. Buck K., Ferger B. l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective. Drug Discov. Today 2010, 15:867-875.
4. Calabresi P., Di F.M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010, 9:1106-1117.
5. Cenci M.A., Lundblad M. Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. 2007, 9(25). (9.25.1-9.25.23).
6. Chen J.F., Moratalla R., Impagnatiello F., Grandy D.K., Cuellar B., Rubinstein M., Beilstein M.A., Hackett E., Fink J.S., Low M.J., Ongini E., Schwarzschild M.A. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1970-1975.
7. Chenn A., Levin M.E., McConnell S.K. Temporally and spatially regulated expression of a candidate G-protein-coupled receptor during cerebral cortical development. J. Neurobiol. 2001, 46:167-177.
8. Chiueh C.C., Krishna G., Tulsi P., Obata T., Lang K., Huang S.J., Murphy D.L. Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: effects of MPP+. Free Radic. Biol. Med. 1992, 13:581-583.
9. Collins A.G., Frank M.J. How much of reinforcement learning is working memory, not reinforcement learning? A behavioral, computational, and neurogenetic analysis. Eur. J. Neurosci. 2012, 35:1024-1035.
10. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego, CA.
11. Heiman M., Schaefer A., Gong S., Peterson J.D., Day M., Ramsey K.E., Suarez-Farinas M., Schwarz C., Stephan D.A., Surmeier D.J., Greengard P., Heintz N. A translational profiling approach for the molecular characterization of CNS cell types. Cell 2008, 135:738-748.
12. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., Hollingsworth Z.R., Collin F., Synek B., Holmans P.A., Young A.B., Wexler N.S., Delorenzi M., Kooperberg C., Augood S.J., Faull R.L., Olson J.M., Jones L., Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
13. 2+ release by activating the sphingosine-kinase pathway. Biochem. Biophys. Res. Commun. 2003, 311:329-336.
14. Kim D.S., Szczypka M.S., Palmiter R.D. Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J. Neurosci. 2000, 20:4405-4413.
15. Kravitz A.V., Freeze B.S., Parker P.R., Kay K., Thwin M.T., Deisseroth K., Kreitzer A.C. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466:622-626.
16. Kreitzer A.C., Malenka R.C. Striatal plasticity and basal ganglia circuit function. Neuron 2008, 60:543-554.
17. Kumer S.C., Vrana K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 1996, 67:443-462.
18. Lobo M.K., Cui Y., Ostlund S.B., Balleine B.W., Yang X.W. Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Gpr6. Nat. Neurosci. 2007, 10:1395-1397.
19. Logue S.F., Grauer S.M., Paulsen J., Graf R., Taylor N., Sung M.A., Zhang L., Hughes Z., Pulito V.L., Liu F., Rosenzweig-Lipson S., Brandon N.J., Marquis K.L., Bates B., Pausch M. The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?. Mol. Cell. Neurosci. 2009, 42:438-447.
20. Meissner W.G., Frasier M., Gasser T., Goetz C.G., Lozano A., Piccini P., Obeso J.A., Rascol O., Schapira A., Voon V., Weiner D.M., Tison F., Bezard E. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 2011, 10:377-393.
21. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
22. Obata T., Yamanaka Y., Chiueh C.C. In vivo release of dopamine by perfusion of 1-methyl-4-phenylpyridinium ion in the striatum with a microdialysis technique. Jpn. J. Pharmacol. 1992, 60:311-313.
23. Oeckl P., Ferger B. Simultaneous LC-MS/MS analysis of the biomarkers cAMP and cGMP in plasma, CSF and brain tissue. J. Neurosci. Methods 2012, 203:338-343.
24. Padmanabhan S., Myers A.G., Prasad B.M. Constitutively active GPR6 is located in the intracellular compartments. FEBS Lett. 2009, 583:107-112.
25. Pardo M., Lopez-Cruz L., Valverde O., Ledent C., Baqi Y., Muller C.E., Salamone J.D., Correa M. Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A(2A)R KO mice. Behav. Brain Res. 2013, 247:217-226.
26. Pivonello R., Ferone D., Lombardi G., Colao A., Lamberts S.W., Hofland L.J. Novel insights in dopamine receptor physiology. Eur. J. Endocrinol. 2007, 156(Suppl. 1):S13-S21.
27. Roth R.B., Hevezi P., Lee J., Willhite D., Lechner S.M., Foster A.C., Zlotnik A. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 2006, 7:67-80.
28. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 2004, 44:269-296.
29. Tanaka S., Ishii K., Kasai K., Yoon S.O., Saeki Y. Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowth. J. Biol. Chem. 2007, 282:10506-10515.
30. Uhlenbrock K., Gassenhuber H., Kostenis E. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell. Signal. 2002, 14:941-953.
31. Xiao M.F., Xu J.C., Tereshchenko Y., Novak D., Schachner M., Kleene R. Neural cell adhesion molecule modulates dopaminergic signaling and behavior by regulating dopamine D2 receptor internalization. J. Neurosci. 2009, 29:14752-14763.
32. Yin H., Chu A., Li W., Wang B., Shelton F., Otero F., Nguyen D.G., Caldwell J.S., Chen Y.A. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J. Biol. Chem. 2009, 284:12328-12338.
33. Zaccolo M., Movsesian M.A. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res. 2007, 100:1569-1578.